March 12, 2026 healthcaremissouri

Hawley Cites Debunked Study to Push Mifepristone Ban His Own Voters Oppose

Truth Score False

22 / 100

The Statement

“The science is clear: the chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it. That’s why I am introducing new legislation to ban the use of mifepristone for abortion and empower women to sue its manufacturers.”

— Sen. Josh Hawley, March 11, 2026, press conference introducing S.4066, the “Safeguarding Women from Chemical Abortion Act”

“Because the drug comes in capsule form and because it is at this juncture, nearly completely unregulated, it is inherently prone to abuse.”

— Sen. Josh Hawley, March 11, 2026

“Only Congress can withdraw the FDA approval rendered way back in the Clinton administration for this drug that has proved to be inherently dangerous.”

— Sen. Josh Hawley, March 12, 2026

Claim-by-Claim Fact Check

Claim	Verdict
Nearly 11% of women experience serious adverse events from mifepristone	FALSE — This figure comes from an Ethics & Public Policy Center (EPPC) report that has been widely debunked. The EPPC study was not peer-reviewed, did not disclose its data source, and inflated its numbers by counting any ER visit within 45 days as a “serious adverse event.” The FDA’s own clinical trial data — over 30,000 patients across 10 studies — puts serious adverse events at under 0.5%. Over 100 studies confirm that more than 99% of patients have no serious complications.
Mifepristone is “nearly completely unregulated”	FALSE — Mifepristone remains subject to the FDA’s Risk Evaluation and Mitigation Strategy (REMS), one of the most restrictive drug safety programs in the country. It requires certified prescribers, certified pharmacies, and a patient agreement. It is more regulated than the vast majority of prescription drugs. What the FDA did was update dispensing rules — removing the in-person-only requirement and allowing certified pharmacy dispensing — based on 20+ years of safety data. Updating regulations based on evidence is not the same as removing them.
Mifepristone is “inherently dangerous”	FALSE — The American College of Obstetricians and Gynecologists (ACOG), the American Medical Association (AMA), and the FDA all affirm that mifepristone is safe and effective. It has been approved for over 25 years. Abortion via mifepristone has a lower complication rate than colonoscopy or tonsillectomy. Out of approximately 7.5 million uses since 2000, the FDA reports 36 associated deaths — a rate that cannot be definitively attributed to the drug due to co-existing conditions and concurrent treatments.
The drug is “inherently prone to abuse” because it comes in capsule form	MISLEADING — Hawley cited roughly a dozen criminal cases of men lacing women’s food or drinks with mifepristone to force an abortion. These cases are real and deeply disturbing — but they represent criminal acts by individuals, not evidence that the drug itself is unsafe. By this logic, any medication in pill or capsule form would be “inherently prone to abuse.” The criminal justice system already addresses these cases through assault and poisoning statutes.
Women need the right to sue mifepristone manufacturers	POLICY CLAIM — This is a legitimate policy proposal. We note it without scoring it as true or false. Whether tort liability should extend to manufacturers of FDA-approved drugs taken as directed is a genuine legal and policy debate.

Analysis

Factor 1: Factual Accuracy — 25%

The foundation of Hawley’s argument is the EPPC study claiming a 10.93% adverse event rate for mifepristone. This study has been dismantled by multiple independent analyses:

KFF (Kaiser Family Foundation) called the report’s findings a “distortion” used to “amplify false claims that mifepristone is unsafe.”

ANSIRH (University of California, San Francisco) published a point-by-point rebuttal showing the study inflated its numbers by:

Counting any ER visit within 45 days as a “serious adverse event” (the actual hospitalization rate was 0.66%, not the 4.6% ER visit rate)
Including mental health diagnoses within 45 days that had no demonstrated connection to the medication
Using an undefined “other abortion-specific complications” category
Refusing to disclose the specific insurance claims database used, making independent verification impossible

The Washington Post fact-checked the study and found the same methodological problems.

STAT News called it a “sloppy report” being used to undermine the FDA and the broader biotech industry.

When the EPPC’s own data is broken down by the categories the FDA actually uses to define serious adverse events, the numbers align with established research: sepsis at 0.10%, blood transfusion at 0.15%, and life-threatening events at 0.22%.

Hawley’s claim that mifepristone is “nearly completely unregulated” is flatly incorrect. The REMS restrictions remain in place. What changed is how the drug is dispensed — and those changes were made by the FDA based on two decades of real-world safety evidence.

Rating: Predominantly False

Factor 2: Intent to Mislead — 20%

Several elements suggest Hawley is aware his framing distorts the evidence:

1. Choosing the EPPC study over the FDA’s own data. Hawley’s office cited “one recent study” showing 11% adverse events. He did not mention that the FDA — the actual regulatory authority — puts the rate at under 0.5%. He did not mention that over 100 peer-reviewed studies support the FDA’s assessment. Citing a single non-peer-reviewed advocacy report while ignoring the overwhelming consensus is a deliberate framing choice.

2. “Unregulated” vs. “updated.” Hawley is a former state attorney general. He understands the difference between removing a regulation and updating dispensing requirements based on evidence. Describing evidence-based regulatory updates as making a drug “nearly completely unregulated” is a mischaracterization he would catch if made by an opposing counsel.

3. Conflating criminal misuse with drug safety. The cases of men poisoning women with mifepristone are horrifying — but they are crimes committed by people, not evidence that a drug is unsafe. Hawley framed these criminal acts as evidence of a drug safety problem rather than a criminal justice problem. This conflation serves the narrative but does not hold up to scrutiny.

A note on fairness: Hawley holds sincere pro-life convictions, and many Americans share his moral framework on abortion. Opposition to mifepristone is a legitimate policy position. But advancing that position with demonstrably false statistics and misleading characterizations of FDA regulation crosses the line from policy advocacy into factual misrepresentation.

Rating: Deliberate Misframing of Evidence

Factor 3: Context & Cherry-Picking — 20%

Topic	What Hawley Said	What He Left Out
Adverse event rate	”Nearly 11%” from EPPC study	FDA says under 0.5%. Over 100 studies confirm 99%+ safety rate. The EPPC study was not peer-reviewed, did not disclose its data, and inflated its numbers by counting ER visits as serious adverse events.
Regulation	”Nearly completely unregulated”	Mifepristone still has REMS restrictions — certified prescribers, certified pharmacies, patient agreements. It is among the most regulated prescription drugs in the country.
Safety protocol changes	Implied safety protections were “removed”	The FDA updated dispensing rules based on 20+ years of safety data. This is how evidence-based regulation is supposed to work.
Medical consensus	Cited EPPC and AAPLOG (a pro-life medical group)	Did not mention that ACOG, AMA, and the FDA all affirm mifepristone’s safety. These represent the overwhelming mainstream medical consensus.
Missouri voters	Did not address	Missouri voters passed Amendment 3 in November 2024 with 52% support, enshrining reproductive freedom protections in the state constitution. Hawley is pursuing a federal ban that directly overrides his own constituents’ expressed will.
Drug comparison	Called mifepristone “inherently dangerous”	Medication abortion has a lower complication rate than colonoscopy, tonsillectomy, and wisdom tooth extraction. Tylenol causes more liver-related ER visits annually.

Rating: Significant Omissions Across Every Major Claim

The Irony

On November 5, 2024, Missouri voters passed Amendment 3 — the Right to Reproductive Freedom Initiative — with approximately 52% of the vote. The amendment enshrined the right to abortion care in the Missouri Constitution, overturning the state’s near-total ban.

Sixteen months later, their senior U.S. senator introduced a federal bill to ban the most common method of abortion in America.

Mifepristone accounts for roughly 63% of all abortions in the United States, according to the Guttmacher Institute. A federal ban on mifepristone would effectively override Amendment 3 for the majority of Missouri women seeking abortion care — undoing what voters chose to protect.

Hawley has not publicly addressed how his bill squares with Amendment 3. He represents all Missourians, including the majority who voted to protect reproductive freedom. Pursuing a federal workaround to a state constitutional amendment his own voters approved raises a fundamental question about representative democracy.

To be clear: senators are not bound to vote in lockstep with their constituents on every issue, and Hawley’s pro-life position predates Amendment 3. But when you build your brand on fighting for the people of Missouri against out-of-touch elites, introducing legislation that overrides a Missouri ballot initiative is a contradiction worth noting.

Follow the Money

In the interest of full transparency: We found no direct financial link between Hawley’s pharmaceutical donors and this bill. Hawley does not appear to be a major recipient of contributions from pharmaceutical or abortion-related industries.

This matters because accountability journalism must be honest even when the data doesn’t tell a convenient story. Not every political action has a donor-driven explanation. In this case, Hawley’s motivation appears to be ideological rather than financial — he holds sincere pro-life beliefs and has been consistent on the issue.

The concern with this bill is not about money. It is about using debunked data to advance a policy position and overriding his own constituents’ vote.

Source: OpenSecrets — Josh Hawley Campaign Finance

Bottom Line

Hawley’s central statistic is false. The 11% adverse event rate comes from a non-peer-reviewed EPPC report that has been debunked by KFF, ANSIRH, the Washington Post, and STAT News. The FDA’s data, based on 30,000+ clinical trial patients and 7.5 million real-world uses, puts serious adverse events at under 0.5%.
His regulatory claims are false. Mifepristone is not “nearly completely unregulated.” It remains under REMS restrictions and is one of the most regulated prescription drugs in America. The FDA updated dispensing rules based on evidence — that is not deregulation.
His “prone to abuse” argument is misleading. Roughly a dozen criminal cases of men poisoning women are evidence of criminal behavior, not drug safety failure. Any pill can be misused by criminals.
He is overriding his own constituents. Missouri voters approved Amendment 3 by 52% in November 2024. A federal mifepristone ban would undercut the reproductive freedom protections Missourians chose to enshrine in their constitution.
The abortion debate has sincere participants on both sides. Hawley’s pro-life convictions are genuine. But genuine convictions do not excuse citing debunked data or mischaracterizing federal regulation. You can advocate for your values without misrepresenting the facts.
No donor angle here — and we say so honestly. We found no financial motivation for this bill. This appears to be ideologically driven, which makes the factual misrepresentations a choice, not a financial incentive.